Literature DB >> 29133573

The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.

Qian Zhong1, Zhi-Hua Liu1,2, Zhi-Rui Lin1, Ze-Dong Hu3, Li Yuan1, Yan-Min Liu1, Ai-Jun Zhou1, Li-Hua Xu4, Li-Juan Hu5, Zi-Feng Wang1, Xin-Yuan Guan1, Jia-Jie Hao6, Vivian W Y Lui7, Ling Guo1,8, Hai-Qiang Mai1,8, Ming-Yuan Chen1,8, Fei Han1,8, Yun-Fei Xia1,9, Jennifer R Grandis10, Xing Zhang11, Mu-Sheng Zeng11.   

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) is the most common head and neck cancer in Southeast Asia. Because local recurrence and distant metastasis are still the main causes of NPC treatment failure, it is urgent to identify new tumor markers and therapeutic targets for advanced NPC.Experimental Design: RNA sequencing (RNA-seq) was applied to look for interchromosome translocation in NPC. PCR, FISH, and immunoprecipitation were used to examine the fusion gene expression at RNA, DNA, and protein levels in NPC biopsies. MTT assay, colony formation assay, sphere formation assay, co-immunoprecipitation, chromatin immunoprecipitation assay, and in vivo chemoresistance assay were applied to explore the function of RARS-MAD1L1 in NPC.
Results: We demonstrated that RARS-MAD1L1 was present in 10.03% (35/349) primary NPC biopsies and 10.7% (9/84) in head and neck cancer (HNC) samples. RARS-MAD1L1 overexpression increased cell proliferation, colony formation, and tumorigenicity in vitro, and the silencing of endogenous RARS-MAD1L1 reduced cancer cell growth and colony formation in vitro In addition, RARS-MAD1L1 increased the side population (SP) ratio and induced chemo- and radioresistance. Furthermore RARS-MAD1L1 interacted with AIMP2, which resulted in activation of FUBP1/c-Myc pathway. The silencing of FUBP1 or the administration of a c-Myc inhibitor abrogated the cancer stem cell (CSC)-like characteristics induced by RARS-MAD1L1. The expression of c-Myc and ABCG2 was higher in RARS-MAD1L1-positive HNC samples than in negative samples.Conclusions: Our findings indicate that RARS-MAD1L1 might contribute to tumorigenesis, CSC-like properties, and therapeutic resistance, at least in part, through the FUBP1/c-Myc axis, implying that RARS-MAD1L1 might serve as an attractive target for therapeutic intervention for NPC. Clin Cancer Res; 24(3); 659-73. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29133573      PMCID: PMC5796860          DOI: 10.1158/1078-0432.CCR-17-0352

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  57 in total

1.  Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding mechanism for the spindle checkpoint.

Authors:  Lucia Sironi; Marina Mapelli; Stefan Knapp; Anna De Antoni; Kuan-Teh Jeang; Andrea Musacchio
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 2.  Essential nontranslational functions of tRNA synthetases.

Authors:  Min Guo; Paul Schimmel
Journal:  Nat Chem Biol       Date:  2013-03       Impact factor: 15.040

3.  MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.

Authors:  Chi Wai So; Holger Karsunky; Emmanuelle Passegué; Antonio Cozzio; Irving L Weissman; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

4.  Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.

Authors:  Li Yuan; Zhi-Hua Liu; Zhi-Rui Lin; Li-Hua Xu; Qian Zhong; Mu-Sheng Zeng
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

5.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

6.  Comprehensive high-throughput RNA sequencing analysis reveals contamination of multiple nasopharyngeal carcinoma cell lines with HeLa cell genomes.

Authors:  Michael J Strong; Melody Baddoo; Asuka Nanbo; Miao Xu; Adriane Puetter; Zhen Lin
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 7.  ABCG2: the key to chemoresistance in cancer stem cells?

Authors:  Yi An; Weg M Ongkeko
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-12       Impact factor: 4.481

8.  A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif.

Authors:  R Duncan; L Bazar; G Michelotti; T Tomonaga; H Krutzsch; M Avigan; D Levens
Journal:  Genes Dev       Date:  1994-02-15       Impact factor: 11.361

9.  MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells.

Authors:  Wen-Jun Wang; Si-Pei Wu; Jia-Bin Liu; Yong-Sheng Shi; Xue Huang; Qian-Bing Zhang; Kai-Tai Yao
Journal:  Cancer Res       Date:  2012-12-26       Impact factor: 12.701

10.  Constitutive Mad1 targeting to kinetochores uncouples checkpoint signalling from chromosome biorientation.

Authors:  Maria Maldonado; Tarun M Kapoor
Journal:  Nat Cell Biol       Date:  2011-03-13       Impact factor: 28.824

View more
  22 in total

Review 1.  The molecular march of primary and recurrent nasopharyngeal carcinoma.

Authors:  Nicholas J Campion; Munira Ally; Bernhard J Jank; Jahangir Ahmed; Ghassan Alusi
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 9.867

2.  RNA-Seq analysis of peripheral blood mononuclear cells reveals unique transcriptional signatures associated with radiotherapy response of nasopharyngeal carcinoma and prognosis of head and neck cancer.

Authors:  Guohong Liu; Xiaojiao Zeng; Balu Wu; Jin Zhao; Yunbao Pan
Journal:  Cancer Biol Ther       Date:  2019-11-07       Impact factor: 4.742

3.  NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3.

Authors:  Yiwei Li; Lijuan Chen; Lixing Feng; Mengli Zhu; Qiang Shen; Yanfen Fang; Xuan Liu; Xiongwen Zhang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

4.  miR-96-5p Suppresses the Progression of Nasopharyngeal Carcinoma by Targeting CDK1.

Authors:  Xiaoqin Luo; Xian He; Xing Liu; Lunkun Zhong; Wenjian Hu
Journal:  Onco Targets Ther       Date:  2020-07-30       Impact factor: 4.147

Review 5.  The master regulator FUBP1: its emerging role in normal cell function and malignant development.

Authors:  Lydie Debaize; Marie-Bérengère Troadec
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

Review 6.  Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer.

Authors:  Zheng Zhou; Bao Sun; Shiqiong Huang; Dongsheng Yu; Xiaochuan Zhang
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

7.  Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis.

Authors:  Lihui Liu; Wenji Xie; Pei Xue; Zixuan Wei; Xiao Liang; Nianyong Chen
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

Review 8.  Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.

Authors:  He-Ming Zhou; Ji-Gang Zhang; Xue Zhang; Qin Li
Journal:  Signal Transduct Target Ther       Date:  2021-02-15

9.  MIAT inhibits proliferation of cervical cancer cells through regulating miR-150-5p.

Authors:  Yanbin Liu; Xingzhi Li; Hui Zhang; Yali Huang
Journal:  Cancer Cell Int       Date:  2020-06-15       Impact factor: 5.722

10.  Cancer stem cell-like characteristics and telomerase activity of the nasopharyngeal carcinoma radioresistant cell line CNE-2R.

Authors:  Kai-Hua Chen; Ya Guo; Ling Li; Song Qu; Wei Zhao; Qi-Teng Lu; Qi-Yan Mo; Bin-Bin Yu; Lei Zhou; Guo-Xiang Lin; Yong-Chu Sun; Xiao-Dong Zhu
Journal:  Cancer Med       Date:  2018-08-13       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.